Abstract 17138: Are Patients With Diabetes Mellitus at Increased Risk for Adverse Outcomes After Left Ventricular Assist Device Implantation? A Systematic Review and Meta-Analysis

Abstract

Background: Patients with diabetes mellitus (DM) are known to have reduced life expectancy and be at increased risk for multiple morbidities including serious infection. However, published data on DM outcomes after left ventricular assist device (LVAD) implantation are sparse, inconsistent and individual studies are small with limited power. We conducted a systematic review and meta-analysis to compare survival and adverse events post-LVAD in DM versus non-DM (NDM) patients. Methods: Medline, Scopus and Cochrane Central databases were searched for studies comparing outcomes in DM and NDM patients undergoing LVAD implantation for advanced heart failure (HF) from inception-February 2018. Outcomes included all-cause mortality (30-day and one-year), device-related infection, ischemic stroke, hemorrhagic stroke and major bleeding. Results were reported as random effect risk ratios (RR) with 95 % confidence intervals. Results: We identified 5 retrospective cohort studies, at low risk of bias, reporting on 1,351 patients (n=488 DM). There was a borderline significant, increased 30-day mortality (RR: 1.57 [1.00, 2.47]; p=0.05; I 2 =0%) among DM vs. NDM. The DM and NDM groups did not differ significantly in terms of 1-year mortality (RR: 1.15 [0.98, 1.35]; p=0.08; I 2 =39%), device-related infection (RR: 1.05 [0.92, 1.19]; p=0.88; I 2 =0%), ischemic stroke (RR: 1.29 [0.91, 1.83]; p=0.69; I 2 =0%), hemorrhagic stroke (RR: 1.10 [0.42, 2.83]; p=0.85; I 2 =69%), and bleeding (RR: 1.06 [0.80, 1.40]; p=0.70; I 2 =27%). Conclusion: Following LVAD implantation, patients with DM, versus patients without, have a modestly elevated 30-day mortality rate. However, 1-year mortality rates, device related infection, and bleeding rates were not different.